58 results on '"Trzaskoma A"'
Search Results
2. Neuronal activation affects the organization and protein composition of the nuclear speckles
3. Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis
4. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
5. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma
6. Characteristics of patients with chronic spontaneous urticaria who are late-responders to omalizumab
7. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis
8. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
9. Effect of sports background on the visual and vestibular signal processing abilities of athletes
10. Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life
11. Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma
12. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies
13. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria
14. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients
15. Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy
16. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma
17. Corrigendum to ‘Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis’ [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077]
18. Balance assessment in hearing-impaired children
19. Stretch-shortening cycle characteristics during vertical jumps carried out with small and large range of motion
20. POST HOC ANALYSIS OF CLINICAL CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) BY PULMONARY VASCULAR PHENOTYPE FROM CAPACITY
21. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab
22. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis
23. Severity of Asthma Score Predicts Clinical Outcomes in Patients With Moderate to Severe Persistent Asthma
24. IMPACT OF BASELINE CHARACTERISTICS ON LONG-TERM RESPONSE FOLLOWING OMALIZUMAB TREATMENT IN PATIENTS WITH ALLERGIC ASTHMA
25. TIME TO SLEEP IMPROVEMENT IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA TREATED WITH OMALIZUMAB
26. IMPACT OF BASELINE ANGIOEDEMA AND IGE ON RESPONSE TO OMALIZUMAB IN CHRONIC SPONTANEOUS URTICARIA
27. Improvements In The Respiratory-Related Patient-Reported Outcomes AQLQ and miniRQLQ Are Similar Across Different Omalizumab Dosing Regimens
28. Amantadine for weight gain associated with olanzapine treatment
29. IMPROVEMENTS IN SELECT PATIENT-REPORTED OUTCOMES ARE SIMILAR ACROSS DIFFERENT OMALIZUMAB DOSING REGIMENS
30. EFFECT OF SEX ON RESPONSE TO OMALIZUMAB IN PATIENTS WITH ASTHMA
31. TIME TO CLINICALLY MEANINGFUL RESPONSE TO OMALIZUMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA
32. PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA MAY BENEFIT FROM LONGER TREATMENT OR UPDOSING WITH OMALIZUMAB
33. EFFICACY OF PIRFENIDONE ON DYSPNEA IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): RESULTS FROM A POST HOC RESPONDER ANALYSIS
34. REDUCTIONS IN EXACERBATIONS AND HOSPITALIZATIONS ARE SIMILAR ACROSS DIFFERENT OMALIZUMAB DOSING REGIMENS
35. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria
36. A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures
37. Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria
38. Baseline Blood Eosinophils and Reduction of Asthma Exacerbations By Omalizumab in Children with Moderate-to-Severe Allergic Asthma
39. Clinically Significant Improvements in Asthma Patient-Reported Outcomes: Results from the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study
40. Decreased Asthma Exacerbations and Hospitalizations in PROSPERO (Prospective Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab)
41. O020 Asthma exacerbations and lung function decline in children during a 52-week controlled trial of omalizumab
42. P147 Omalizumab reduces healthcare resource use in children
43. P144 Exacerbation-free asthma in children treated with omalizumab
44. Exploratory Analysis of the Roles of Multiple Biomarkers in Predicting Response to Omalizumab in Allergic Asthma
45. Poor Asthma Control Is Associated with Overall Daily Activity Impairment: 3-Year Data from the EXCELS Study of Omalizumab
46. Blood Eosinophils and Serum IgE Predict Response to Omalizumab in Patients with Severe Allergic Asthma: Innovate Trial Post-Hoc Analysis
47. Biomarkers Associated with Response in Patients Initiating Omalizumab: Baseline Levels Among Patients in the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study
48. Response Patterns in Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Patients Treated with Omalizumab for 24 Weeks in Two Randomized, Double-Blind, Placebo-Controlled Clinical Trials (ASTERIA I and GLACIAL)
49. Estimated Asthma Exacerbation Reduction from Omalizumab in an Severe Eosinophilic Asthma Population
50. Improvements In Health-Related Quality Of Life From Asteria I & II: Phase III Studies To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.